Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Full-field deep ablative laser resurfacing is a popular method for skin rejuvenation due to maximum improvement in a single treatment. However, it is associated with disadvantages such as pain, prolonged erythema, swelling, crusting, infections, pigmentary changes, and scarring. Patients are increasingly seeking less invasive options with comparable effect. The aim of this retrospective study was to evaluate the safety and efficacy of full-face resurfacing using a combination of full spot and fractional erbium (Er:YAG) laser resurfacing. About 109 patients, mostly females over 50 years old, were treated with a two-phase protocol: full spot ablation (5 J/cm2 , three passes) and fractional ablation (132 J/cm2 , 5% coverage, three passes). We recorded time to re-epithelization and duration of post-treatment erythema. Any side effects observed at follow-up or reported by the patient were recorded. Patient satisfaction questionnaire and blinded evaluation of pre- and post-treatment photographs were used to assess efficacy. A single session was performed in 96% of cases. Postoperative re-epithelization lasted on average 6.4 ± 2.9 days. Post-treatment erythema lasted on average 13.8 ± 15.2 days. One patient had hyperpigmentation, one infection, one hypo-pigmentation, and one ulcer. All side effects resolved without complications. According to the blinded assessment of photographs, 78% of patients showed improvement. About 97% of patients were satisfied with the results of the treatment. A combination of fractional and full spot ablative Er:YAG laser is a safe and effective option for full-face resurfacing. © 2020 Wiley Periodicals, Inc.

Citation

Nasrin Mani, Franja Pajk, Zdenko Vizintin. Full-face skin resurfacing using a combination of fractional and full spot ablative 2940 nm erbium laser. Journal of cosmetic dermatology. 2021 Jan;20(1):110-115

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32319157

View Full Text